BRD9抑制剂的未来:一个专利前景 (2019年至今)
Eleonora Boccia1, Stefania Terracciano1, Maria Giovanna Chini2
1Department of Pharmacy, University of Salerno, Fisciano, Italy.
Expert opinion on therapeutic patents
|December 18, 2025
概括
最近的专利表明,选择性BRD9降解剂是一种有前途的治疗策略. 这些化合物向含有odomain的蛋白9 (BRD9) 表观遗传阅读器,在AML和亨廷顿病等疾病的临床前模型中显示有效性.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 含原蛋白9 (BRD9) 是非正规BAF (ncBAF) 染色体重塑复合物的关键组成部分.
- BRD9在转录调节中的作用使其成为各种疾病的重要治疗点.
- 由于BRD9,GLTSCR1和GLTSCR1L等独特的子单元,ncBAF复合体是不同的.
研究的目的:
- 从2019-2025年审查专利,重点关注针对BRD9活性的化合物.
- 分析专利环境,寻找干扰BRD9.9的小分子和PROTACs (蛋白质降解剂).
- 根据最近的专利申请,评估针对BRD9的治疗潜力.
主要方法:
- 在欧洲专利局 (EPO) 和世界知识产权组织 (WIPO) 数据库中搜索相关专利.
- 确定并分析了针对BRD9.9的小分子和PROTAC的专利.
- 审查了专利数据,重点关注2019年至2025年间开发的化合物.
主要成果:
- 在专利领域,人们对BRD9作为表观遗传标的兴趣日益增长.
- 选择性BRD9降解剂在有效性和选择性方面取得了重大进展.
- 在AML,SS和HD模型中观察到BRD9降解剂的前临床结果很有希望.
结论:
- 选择性降解BRD9是一种潜在的创新治疗策略.
- BRD9降解剂在治疗各种病理方面显示出显著的前景.
- 尽管面临挑战,但针对BRD9提供了一种新的治疗方法.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
FDA Approved Drugs: Changes to Approved Drugs
214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Biopharmaceutical Factors Influencing Drug Product Design: Overview
212
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
212
Structure-Activity Relationships and Drug Design
1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Microorganisms in Medicine and Therapeutics
908
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
908
Bioequivalence studies: Biowaivers
197
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
197


